This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights: CLX, MRNA, TDOC and ATVI
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CLX, MRNA, TDOC and ATVI
Teladoc (TDOC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $118.24, moving +1.28% from the previous trading session.
4 Stocks That Will Survive the Coronavirus Collapse
by Nilanjan Banerjee
Although the Wall Street's 11-year bull run has come to a halt abruptly, it doesn't signify the end for all.
Teladoc Witnesses Higher Visits Due to Coronavirus Outbreak
by Zacks Equity Research
Teladoc's (TDOC) teleheath services are witnessing increase in demand due to coronavirus outbreak.
The Zacks Analyst Blog Highlights: HENKY, NFLX, PTON, TDOC and GILD
by Zacks Equity Research
The Zacks Analyst Blog Highlights: HENKY, NFLX, PTON, TDOC and GILD
4 Sectors in Focus Following Coronavirus-Induced Selloff
by Urmimala Biswas
While COVID-19 has dealt a huge blow to most sectors, it has opened up enormous opportunities for a few.
Implied Volatility Surging for Teladoc Health (TDOC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Teladoc health (TDOC) stock based on the movements in the options market lately.
Teladoc (TDOC) Up 49% Year to Date: Will the Rally Continue?
by Zacks Equity Research
Teladoc (TDOC) benefits from its fast growing healthcare business and international expansion.
Can Telemedicine be a Market Savior on Rising Corona Scare?
by Urmimala Biswas
Here are four telemedicine stocks which have robust prospects to become attractive picks on the COVID-19 economic doldrums.
Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FNY
Teladoc (TDOC) Hits New 52-Week High on Strong Q4 Results
by Zacks Equity Research
Teladoc (TDOC) reaches new 52-week high in the trading session on Feb 27 on impressive fourth-quarter results.
Teladoc (TDOC) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Teladoc's (TDOC) Q4 results reflect strong revenue growth, partially offset by high expenses.
Teladoc (TDOC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 21.21% and 1.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Teladoc's (TDOC) Q4 performance is likely to have benefited from increased membership and visits.
Molina Healthcare (MOH) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Molina Healthcare's (MOH) fourth-quarter results are likely to reflect lower premium revenues and decline in medical membership.
Teladoc (TDOC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed at $107.06 in the latest trading session, marking a -0.08% move from the prior day.
Cigna (CI) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Cigna's (CI) earnings performance is likely to have gained from the accretive Express Scripts acquisition.
Centene's (CNC) Q4 Earnings Miss Estimates, Improve Y/Y
by Zacks Equity Research
Centene's (CNC) fourth-quarter results gain traction from better revenues.
What's in the Cards for Centene's (CNC) Earnings in Q4?
by Zacks Equity Research
Centene's (CNC) Q4 earnings results are likely to reflect membership growth and better revenues.
Teladoc (TDOC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $104.75, moving +1.23% from the previous trading session.
Anthem's (ANTM) Q4 Earnings Miss Estimates, Rise Y/Y
by Zacks Equity Research
Anthem's (ANTM) fourth-quarter results reflect solid revenues, partially offset by increased expenses.
HCA Healthcare (HCA) Q4 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
HCA Healthcare's (HCA) Q4 results gain traction from better revenues and increased admissions.
Anthem (ANTM) Gears Up for Q4 Earnings: What's in Store?
by Zacks Equity Research
Anthem's (ANTM) fourth-quarter results are likely to reflect a strong revenue stream.
What's in Store for HCA Healthcare's (HCA) Q4 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) Q4 results are likely to reflect healthy growth in revenues and admissions.
Teladoc (TDOC) Hits 52-Week High: Will Momentum Sustain?
by Sapna Bagaria
Teladoc (TDOC) stock gains from from positive earnings pre-announcement and news to acquire InTouch Health.